Artiva Biotherapeutics, Inc.
ARTVHealthcare|Biotechnology|US
$4.15
+0.02 (+0.48%)
DCF Value
$0.66
Tangible Book / Share
$8.82
Cash / Share
$8.86
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06991114 AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | P2 | Recruiting | 90 | Open-label | Allogeneic NK Cells |
| NCT06265220 AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | P1 | Active | 51 | Open-label | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| NCT06581562 Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. | Rheumatoid Arthritis, Pemphigus Vulgaris | P1 | Recruiting | 30 | Open-label | AB-101, Rituximab, Cyclophosphamide, Fludarabine |
| NCT06699771 Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | Lymphoma, T-Cell | P1 | Recruiting | 53 | Open-label | GCC2005, Cyclophosphamide, Fludarabine |
| NCT05883449 Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma | P2 | Terminated | 25 | RCT, Open-label | AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2 |
| NCT04673617 AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Non Hodgkin Lymphoma | P1P2 | Completed | 45 | Open-label | AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine |
| NCT05678205 A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Breast Cancer, Gastric Cancer | P1P2 | Withdrawn | — | Open-label | AB-201, Cyclophosphamide, Fludarabine |